VETMEDIN 2.5 MG CHEWABLE TABLETS FOR DOGS

Land: Australia

Språk: engelsk

Kilde: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Aktiv ingrediens:

PIMOBENDAN

Tilgjengelig fra:

Boehringer Ingelheim Animal Health Australia Pty. Ltd.

INN (International Name):

pimobendan(2.5mg/Tb)

Legemiddelform:

ORAL BOLUS, CHEWABLE

Sammensetning:

PIMOBENDAN PYRIDAZINONE Active 2.5 mg/Tb

Enheter i pakken:

50 tabs

Klasse:

VM - Veterinary Medicine

Terapeutisk gruppe:

DOG | BITCH | CASTRATE | PUPPY

Terapeutisk område:

CARDIOVASCULAR SYSTEM

Indikasjoner:

CONGESTIVE HEART FAILURE | DILATED CARDIOMYOPATHY | MITRAL AND/OR TRICUSPID REGUR | VALVULAR INSUFFICIENCY

Produkt oppsummering:

Poison schedule: 4; Withholding period: WHP: N/A; Host/pest details: DOG: [CONGESTIVE HEART FAILURE, PRECLINICAL MYXOMATOUS MITRAL VALVE DISEASE]; DOG - LARGE: [PRECLINICAL DCM, PRECLINICAL MYXOMATOUS MITRAL VALVE DISEASE]; For the treatment of canine congestive heart failure (CHF) originating from dilated cardiomyopathy (DCM) or valvular insufficiency (mitral and/or tricuspid regurgitation).Should NOT be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is NOT recommended for functional or anatomical reasons (e.g. aortic stenosis). See Precautions on label also.

Autorisasjon status:

Registered

Autorisasjon dato:

2023-07-01

Informasjon til brukeren

VETMEDIN 2.5 MG CHEWABLE TABLETS FOR DOGS
60799/109758
Product Name:
APVMA Approval No:
Label Name:
VETMEDIN 2.5 MG CHEWABLE TABLETS FOR DOGS
Signal Headings:
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
Constituent
Statements:
Each tablet contains 2.5 mg pimobendan.
Claims:
Vetmedin ® Chewable Tablets are indicated for:
The treatment of canine congestive heart failure (CHF) originating
from dilated
cardiomyopathy (DCM) or valvular insufficiency ( mitral and/ or
tricuspid regurgitation) .
The treatment of pre-clinical DCM in large breed dogs. When used in
cases of preclinical
DCM in large breed dogs, pimodendan significantly prolonged the time
to the onset of CHF
or sudden death, and also resulted in prolongation of the time to
death due to all causes.
Doberman Pinscher dogs with preclinical DCM treated with pimobendan
also demonstrated
a significant reduction in Left Ventricular Internal Diameter in both
systole and diastole
( LVIDs/d) in response to therapy.
For the treatment of dogs with evidence of increased heart size
secondary to asymptomatic
(preclinical) myxomatous mitral valve disease to delay the onset of
clinical symptoms of
heart failure, to reduce heart size and to increase survival time.
Net Contents:
50 tablets.
Directions for Use:
Restraints:
Contraindications:
This product is contraindicated for use in cases of hypertrophic
cardiomyopathies or clinical
conditions where an augmentation of cardiac output is not recommended
for functional or
anatomical reasons (e.g. aortic stenosis). RLP APPROVED
Precautions:
Vetmedin ® Chewable Tablets should only be administered in pregnant
and lactating
bitches if the expected therapeutics benefits overweigh the potential
risk.
Studies into the effect of pimobendan on the reproductive function of
male dogs have not
been conducted.
In pharmacological studies no interaction between the cardiac
glycoside oubain and
pimobendan was detected. The pimobendan induced increase in
contractility of the heart
is attenuated in the prese

Preparatomtale

CS: 1.9.46
Page:
1
MATERIAL SAFETY DATA SHEET
4
of
Infosafe No™
LQ1I5
September 2012
ISSUED by BOEHRING
Issue Date :
VETMEDIN® CHEWABLE TABLETS FOR DOGS
Product Name :
Not classified as hazardous
1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER
VETMEDIN® CHEWABLE TABLETS FOR DOGS
PRODUCT NAME
Boehringer Ingelheim Pty. Limited
COMPANY NAME
78 Waterloo Rd North Ryde
NSW 2113 Australia
ADDRESS
1800 038 037
EMERGENCY TEL.
Tel: [phone]
Fax: [phone]
TELEPHONE/FAX
NUMBER
[e-mail]
EMAIL
Vetmedin® chewable tablets are indicated for the treatment of canine
congestive heart failure originating from dilated cardiomyopathy or
valvular
insufficiency (mitral and/or tricuspid regurgitation).
RECOMMENDED USE
2. HAZARDS IDENTIFICATION
Not classified as hazardous
NON-HAZARDOUS SUBSTANCE.
NON-DANGEROUS GOODS.
Not Classified as Hazardous according to criteria of National
Occupational
Health & Safety Commission, Australia (NOHSC).
Not Classified as Dangerous Goods according to the Australian Code for
the
Transport of Dangerous Goods by Road and Rail. (7th edition)
HAZARD
CLASSIFICATION
3. COMPOSITION/INFORMATION ON INGREDIENTS
Pimobendan, a benzimidazole-pyridazinone derivative, is a
non-sympathomimentic, non-glycoside
inotropic substance with potent vasodilatative properties.
1.25 mg beef flavoured palatable chewable tablet contains 1.25 mg
pimobendan
5 mg beef flavoured palatable chewable tablet contains 5 mg pimobendan
2.5 mg beef flavoured palatable chewable tablet contains 2.5 mg
pimobendan
INFORMATION ON
COMPOSITION
NAME
RISK PHRASE
CAS
PROPORTION
HAZARD SYMBOL
INGREDIENTS
Pimobendan
(3(2H)-Pyridazinone,
4,5-dihydro-6-[2-
(4-methoxyphenyl)-1H-be
nzimidazol-5-yl]-5-meth
yl-)
74150-27-9
<=2 %
Ingredients determined
not to be hazardous
-
Balance
4. FIRST AID MEASURES
No special precautions required. However, if inhaled, remove affected
person
from contaminated area. Keep at rest until recovered. If symptoms
persist seek
medical attention.
INHALATION
Do not induce vomiting. Wash out mo